Drug repurposing is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case; a holistic gedanken experiment almost needs to be undertaken at the very start of any repurposing development. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. And while repurposing of medicines has been in the mind of every doctor since Hypocrates, modern clinical practice will simply have to adapt to new repurposing techniques in an age where the number of known diseases is increasing much faster than the healthcare dollars available.

This volume addresses efforts to overcome the shortcomings of conventional dosage forms by exploiting the principles of nanoscience to deliver drugs for medical treatment. Nanodispersions are an important aspect because they possess globules/particles in sizes usually below 1000 nm in which the drug is dispersed in a continuous medium employing surface-active agents as stabilizers. With chapters written by experienced scientists and researchers in the field, this volume provides an abundance of information on various aspects of nanodispersions for drug delivery. The book is divided into several sections: nanoemulsions, nanosuspensions, and diverse dispersed systems. The chapters detail what nanodispersions have demonstrated in the past and what they are expoected to continue to do in the future as the technology further evolves. Key features: * Provides an overview of nanoemulsions for drug delivery * Introduces the general principles, classification, and methods of preparation of nanoemulsion-based drug delivery systems * Presents information relevant to specific routes of applications of nanoemulsions * Looks at the various aspects of nanosuspensions, including their formulation components, preparation methods, unique features, methods of characterization, and applications in various routes of administration * Explores nanomicellar approaches for drug delivery * Discusses the preparation, applications, and clinical considerations of nanogels for drug delivery

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials. The author suggests that CMC (chemistry manufacturing controls) drug development must reset the line of sight - from supply of drug to the clinic and gaining a registration, to the building of a patient value stream. Capable processes and suppliers, streamlined logistics, flexible plant and equipment, shorter cycle times, effective flow of information and reduced waste. All these factors can and should be addressed at the CMC development stage.

The first and only book on Spray-freeze-drying" which is a relatively recent drying technique, that provides the signature advantages of spray-drying and freeze-drying, while overcoming the limitations of both. Provides examples and case studies of nuances and intricacies associated with each stage of the spray-freeze-drying process Contains 200+ illustrations and tabulations Highlights the applications of spray-freeze-drying in the production of food products including soluble coffee, dairy powders, probiotics, and flavors.

The book presents an innovative technology based on injection of a very weak current to trace the quantity of a drug carried immediately after the administration. The book makes the reader familiar with the technology, from the conception through the design of the instrument, up to the preliminary clinical applications. In the first chapter, the method of transdermal drug delivery and the use of impedance spectroscopy in the dermatological field are presented. The second chapter describes a screening measurement campaign aimed at proving the feasibility of the assessment method and identifying the bandwidth of interest. The prototyping, validation and characterization of an instrument to measure the amount of drug delivered (DUSM: Drug Under Skin Meter) are presented in chapter three. In the fourth chapter three experimental campaigns, based on the electrical analysis of the biological tissue behavior due to the drug delivery, are reported: (i) laboratory emulation on eggplants, (ii) ex-vivo tests on pig ears, and finally (iii) in-vivo tests on human volunteers. In the fifth chapter a behavioral model, based on Finite Elements and Partial Differential Equation, of an impedance-based measurement system for assessing the drug released under the skin, during transdermal delivering, is proposed. The last chapter is dedicated to present a campaign in order to prove the suitability for insulin therapy applications. This book is intended for biomedical engineers, biomedical engineering students, operators working in the field of biomedical instrumentation, biotechnologists, and technicians of transdermal vehiculation.

Before now, biological systems could only be expressed in terms of linear relationships, however, as knowledge grows and new techniques of analysis on biological systems is made available, we are realizing the non-linearity of these systems. The concepts and techniques of nonlinear analysis allow for more realistic and accurate models in science. The Future of Pharmaceuticals: A Nonlinear Analysis provides an opportunity to understand the non-linearity of biological systems and its application in various areas of science, primarily pharmaceutical sciences. This book will benefit professionals in pharmaceutical industries, academia, and policy who are interested in an entirely new approach to how we will treat disease in the future. Key Features: Addresses a new approach of nonlinear analysis. Applies a theory of projection to chalk out the future, instead of basing on linear evolution. Provides an opportunity to better understand the non-linearity in biological systems and its applications in various areas of science, primarily pharmaceutical sciences. Helps change the thought process for those looking for answers to their questions which they do not find in the linear relationship approach. Encourages a broader perspective for the creative process of drug development.

Before now, biological systems could only be expressed in terms of linear relationships, however, as knowledge grows and new techniques of analysis on biological systems is made available, we are realizing the non-linearity of these systems. The concepts and techniques of nonlinear analysis allow for more realistic and accurate models in science. The Future of Pharmaceuticals: A Nonlinear Analysis provides an opportunity to understand the non-linearity of biological systems and its application in various areas of science, primarily pharmaceutical sciences. This book will benefit professionals in pharmaceutical industries, academia, and policy who are interested in an entirely new approach to how we will treat disease in the future. Key Features: Addresses a new approach of nonlinear analysis. Applies a theory of projection to chalk out the future, instead of basing on linear evolution. Provides an opportunity to better understand the non-linearity in biological systems and its applications in various areas of science, primarily pharmaceutical sciences. Helps change the thought process for those looking for answers to their questions which they do not find in the linear relationship approach. Encourages a broader perspective for the creative process of drug development.

This timely volume explores the impact of autophagy in various human diseases, emphasizing the cell biological aspects and focusing on therapeutic approaches to these diseases. The chapters cover autophagy and its potential applications on diseases ranging from obesity, osteoarthritis, pulmonary fibrosis, and inflammation, through ALS, Parkinson's, retinal degeneration, breast cancer, alcoholic liver disease and more. The final chapters round out the book with a discussion of autophagy in drug discovery and 'bench to bedside'. Chapters are contributed by leading authorities and describe the general concepts of autophagy in health and disease, marrying cell biology and pharmacology and covering: studies derived from preclinical experiments, manufacturing considerations,and regulatory requirements pertaining to drug discovery and manufacturing and production. This volume will be useful for basic scientists as well as already practicing clinicians and advanced graduate students.

This book addresses the highly relevant and complex subject of research on drugs from natural products, discussing the current hot topics in the field. It also provides a detailed overview of the strategies used to research and develop these drugs. Respected experts explore issues involved in the production chain and when looking for new medicinal agents, including aspects such as therapeutic potential, functional foods, ethnopharmacology, metabolomics, virtual screening and regulatory scenarios. Further, the book describes strategic methods of isolation and characterization of active principles, biological assays, biotechnology of plants, synthesis, clinical trials and the use of tools to identity active principles.

Ocimum species has been used as a traditional remedy for various ailments such as arthritis, bronchitis, cold, conjunctivitis, diarrhea, dysentery, and flatulence, as well as for healing wounds and lowering blood glucose level. These are characterized by variations in their morphology such as the shape, size and pigmentation of leaves, which cause differences in chemical composition and affect the commercial value of this genus. This book describes phytochemical investigations of Ocimum species using LC-MS/MS instruments to study qualitative and quantitative variations of phytochemicals in different Ocimum species. Features: Collection of Ayurvedic features and scientific analytical and pharmacological evidence of most important medicinal plants of genus Ocimum. Chemical signatures for the identification of Ocimum species. Easy-to-use analytical procedure for quality control of plants of Ocimum species and its herbal products.

Several Phyllanthus species are widely used in traditional medicine and herbal formulation for the treatment of a variety of ailments such as flu, dropsy, diabetes, jaundice and bladder calculus. The medicinal properties of these species are due to the presence of lignans, flavonoids, tannins, alkaloids and terpenoids. Phyllanthin and hypophyllanthin are the major lignans from Phyllanthus species having estrogenic properties that reduce toxicity and vascular tension, and protect hepatocytes. This book deals with the importance of separation techniques in screening of major lignans, flavonoids and terpenoids in Phyllanthus species using HPLC/UPLC coupled with mass spectrometric techniques. Features: Collection of Ayurvedic features and scientific evidence of important medicinal plants. Screening of major lignans, flavonoids and terpenoids in plant parts/whole plant extracts and their geographical variations in Phyllanthus amarus. Easy-to-use analytical procedure for the quality control of Phyllanthus and its products.

Piper is the representative genus of family Piperaceae. Piper species are pan-tropical in distribution and found in both the hemispheres. As the king of all spices, black pepper, Piper nigrum, led to the global expeditions culminating in the discovery of India and the new world. Piper species have been reported to possess various pharmacological activities such as insecticidal, antibacterial, anti-inflammatory, antiplatelet, anti-hypertensive, antithyroid, antitumor activities and hepatoprotective properties. Botanical authentication of the plants of Piper species is difficult because of the morphological similarity among the species. This book describes ultra-performance liquid chromatography coupled with triple quadrupole electrospray tandem mass spectrometry in multiple reactions monitoring (MRM) mode to study the quantitative variation of thirteen bioactive markers in different plant parts of ten Piper species. Features: Collection of Ayurvedic features and scientific evidence of the most important medicinal plants of Piper species. Describes chemical signatures for identification of Piper species. Provides easy-to-use analytical procedure for quality control of Piper species and its products.

Biotechnology in the Modern Medicinal System: Advances in Gene Therapy, Immunotherapy, and Targeted Drug Delivery presents an informative picture of the state-of-the-art research and development of actionable knowledge in medical biotechnology, specifically involving gene therapy, immunotherapy, and targeted drug delivery systems. The book includes novel approaches for therapy of various ailments and the real-world challenges and complexities of the current drug delivery methodologies and techniques. The volume helps to bridge the gap between academic research and real-time clinical applications and the needs of medical biotechnology methods. This edited book also provides a detailed application of medical biotechnology in drug discovery and the treatment of various deadly diseases. Chapters discuss targeted drug delivery to specific sites to avoid possible entry to non-targeted sites, minimizing adverse effects. The volume provides information about the roles of alternative routes of drug targeting, like intranasal and transdermal, resulting in improving patient compliance. Targeted drug delivery is explored for several health issues, such as neurodegenerative disorders, cancer, malaria, and hemoglobin disorders. Also considered is the role of genes in various genetic diseases and gene therapy, and immunogene therapy as alternative approaches to conventional cancer therapy. Finally, the book investigates the important role of computers in biotechnology to accelerate research and development in the modern medicinal field for better and optimum results. Studies show that significant improvement has been observed in the development of a faster and less invasive diagnostic system for the treatment of diseases by utilizing both artificial intelligence (AI) and biotechnology. This valuable volume provides a wealth of information that will be valuable to scientists and researchers, faculty, and students.

After the drug discovery and development process, designing suitable formulations to safely deliver the optimum dose, while avoiding side effects, has been a constant challenge, especially when drugs are very toxic and have poor solubility and undesirable clearance profiles. With recent advances in synthetic technologies, nanoparticles can be custom-made from a variety of advanced materials to mimic the bioenvironment and can be equipped with various targeting and imaging moieties for site-specific delivery and real-time imaging. Drug Delivery Using Nanomaterials covers advancements in the field of nanoparticle-based drug-delivery systems, along with all the aspects needed for a successful and marketable nanoformulation. FEATURES Offers a general overview of the entire process involved in the synthesis and characterization of pharmaceutical nanoparticles Covers a broad range of synthetic materials for developing nanoformulations customized for specific disease states, target organs, and drugs Every chapter sequentially builds, providing a progressive pathway from classical nanoparticles to the more advanced to be used as a full drug product by consumers Provides information in a bottom-up manner in that definitions and explanations of relevant background information serve as a framework for understanding advanced concepts This user-friendly reference is aimed at materials engineers, chemical engineers, biomedical engineers, pharmaceutical scientists, chemists, and others working on advanced drug delivery, from academia as well as industry.

The new volume takes an interdisciplinary look at current technical challenges and recent developmental trends in microbial biotechnology. It covers an avalanche of new information available through research by focusing on a broad spectrum of issues on different microorganisms and their recent applications and implications in agriculture, soil science and forestry, industry, and public health and medicine. Microbes present in our immediate environment have a direct or indirect influence leading to either a harmful or beneficial effect. Microbial Biotechnology: Technological Challenges and Developmental Trends is divided into four major sections that focus on Part I: Antimicrobial Agents: Role and Applications in Medicine and Health Care Part II: Role of Microorganisms in Agriculture and Plant Biotechnology Part III: Microbial Enzymes and Their Potential Industrial Applications Part IV: Microorganisms in Environment: Role and Industrial Applications Topic include organic chemistry, biomass conversion, optimal production processes for different microbes, screening methods, and application of omics approaches such as (meta) genomics, proteomics, and metabolomics, or other biotechnology tools, to provide a deeper understanding of the microbial-based new and emerging products, trends, processes, and technologies. The chapters present unbiased original research results on microbes by incorporating case studies wherever appropriate. Providing research findings applicable to the development of new methodologies, applications, and technologies, the book will be a valuable resource for people working in various fields of microbiology.

An integrated approach to provide information about all aspects of cancer biology, diagnosis and therapy. Covers both conventional and emerging tools/ techniques applicable in cancer screening and diagnosis. Covers the mechanisms of conventional and emerging anticancer drugs and therapies. Provides insights about personalized medicine based approach in cancer diagnosis and therapy.

This book presents an overview of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. It then focuses on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside. RNAi technique has become a powerful tool for basic research to selectively knock down gene expression in vitro and in vivo. Our scientific and industrial communities have started to develop RNAi therapeutics as the next class of drugs for treating a variety of genetic disorders, such as cancer and other diseases that are particularly hard to address with current treatment strategies. Key Features Provides insight into the current advances and hurdles of RNAi therapeutics. Accelerates RNAi, miRNAs, and siRNA drug development for cancer therapy from bench to bedside. Addresses various modifications and novel delivery strategies for miRNAs, piRNAs and siRNA delivery in anticancer therapeutics. Explores the need for the interaction of hematologists,cell biologists, immunologists, and material scientists in the development of novel cancer therapies. Describes the current status of clinical trials related to miRNA and siRNA-based cancer therapy Presents remaining issues that need to be overcome to establish successful therapies.

Provides a systematic review of microextraction techniques applied in analytical toxicology. A comprehensive guide for practical implementation of microextraction techniques in forensic, clinical and analytical laboratories. Contains figures and tables for easy understanding and quick adaptation of parameters of microextraction techniques. Fundamentals, development, and applications of microextraction techniques as a sample preparation procedure are discussed in detail. Extremely useful for the researchers and academicians engaged in the analytical method development using microextraction techniques.

Covers four pillars of safety statistics: cross-disciplinary scientific engagement, effective and efficient operational process, visual analytics, and intelligent data architecture Links safety monitoring to benefit risk evaluation Presents an emerging topic that links to ICH E19 and TransCelerate safety efforts

We have surpassed the omics era and are truly in the Age of Molecular Therapeutics. The fast-paced development of SARS-CoV-2 vaccines, such as the mRNA vaccines encoding the viral spike protein, demonstrated the need for and capability of molecular therapy and nanotechnology-based solutions for drug delivery. In record speed, the SARS-CoV-2 viral RNA genome was sequenced and shared with the scientific community, allowing the rapid design of molecular therapeutics. The mRNA vaccines exploit the host cell endoplasmic reticulum to produce viral spike proteins for antigen presentation and recognition by the innate and adaptive immune system. Lipid nanoparticles enable the delivery of the fragile, degradation-sensitive nucleic acid payloads. Molecular-based therapeutics and nanotechnology solutions continue to drive the scientific and medical response to the COVID-19 pandemic as new mRNA, DNA, and protein-based vaccines are developed and approved and the emergency use approved vaccines are rapidly manufactured and distributed throughout the globe. The need for molecular therapies and drug delivery solutions is clear, and as these therapies progress and become more specialized there will be important advancements in organelle targeting. For example, using organelle targeting to direct lipid nanoparticles with mRNA payloads to the endoplasmic reticulum would increase the efficacy of mRNA vaccines, reducing the required dose and therefore the biomanufacturing demand. Likewise, improving the delivery of DNA therapeutics to the nucleus would improve efficacy. Organelles and molecules have always been drug targets, but until recently we have not had the tools or capability to design and develop such highly specific therapeutics. Organelle targeting has far-reaching implications. For example, mitochondria are central to both energy production and intrinsic apoptosis. Effectively targeting and manipulating mitochondria has therapeutic applications for diseases such as myopathies, cancer, neurodegeneration, progerias, diabetes, and the natural aging process. The SARS-CoV-2 vaccines that exploit the endoplasmic reticulum (for mRNA vaccines) and the nucleic translational process (DNA vaccines) attest to the need for organelle and molecular therapeutics. This book covers the status, demand, and future of organelle- and molecularly targeted therapeutics that are critical to the advancement of modern medicine. Organelle and molecular targeting is the drug design and drug delivery approach of today and the future; understanding this approach is essential for students, scientists, and clinicians contributing to modern medicine.

Global simultaneous development is becoming more necessary as the cost of developing medical products continues to grow. The strategy of using multiregional clinical trials (MRCTs) has become the preferred method for developing new medicines. Implementing the same protocol to include subjects from many geographical regions around the world, MRCTs can speed up the patient enrolment, thus resulting in quicker drug development and obtaining faster approval of the drug globally. After the publication of the editors' first volume on this topic, there have been new developments on MRCTs. The International Council for Harmonisation (ICH) issued ICH E17, a guideline document on MRCTs, in November 2017, laying out principles on MRCTs. Beyond E17, new methodologies have been developed as well. Simultaneous Global New Drug Development: Multi-Regional Clinical Trials after ICH E17 collects chapters providing interpretations of principles in ICH E17 and new ideas of implementing MRCTs. Authors are from different regions, and from academia and industry. In addition, in contrast to the first book, new perspectives are brought to MRCT from regulatory agencies. This book will be of particular interest to biostatisticians working in late stage clinical development of medical products. It will also be especially helpful for statisticians in regulatory agencies, and medical research institutes. This book is comprehensive across the MRCT topic spectrum, including Issues regarding ICH E17 Implementation MRCT Design and Analysis Methodologies Perspectives from authorities in regulatory agencies, as well as statisticians practicing in the medical product industry Many examples of real-life applications based on actual MRCTs.

Recent regulations on heavy metal testing have required the pharmaceutical industry to monitor a suite of elemental impurities in pharmaceutical raw materials, drug products and dietary supplements. These new directives s are described in the new United States Pharmacopeia (USP) Chapters <232>, <233>, and <2232>, together with Q3D, Step 4 guidelines for elemental impurities, drafted by the ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), a consortium of global pharmaceutical associations, including the European Pharmacopeia (Ph.Eur.), the Japanese Pharmacopeia (JP) and the USP. This book provides a complete guide to the analytical methodology, instrumental techniques and sample preparation procedures used for measuring elemental impurities in pharmaceutical and nutraceutical materials. It offers readers the tools to better understand plasma spectrochemistry to optimize detection capability for the full suite of elemental PDE (Permitted Daily Exposure) levels in the various drug delivery categories. Other relevant information covered in the book includes: The complete guide to measuring elemental impurities in pharmaceutical and nutraceutical materials. Covers heavy metals testing in the pharmaceutical industry from an historical perspective. Gives an overview of current USP Chapters <232> <233> and <2232> and ICH Q3D Step 4 Guidelines. Explains the purpose of validation protocols used in Chapter <233>, including how J-values are calculated Describes fundamental principles and practical capabilities of ICP-MS and ICP-OES. Offers guidelines about the optimum strategy for risk assessment Provides tips on how best to prepare and present your data for regulatory inspection. An indispensable resource, the fundamental principles and practical benefits of ICP-OES and ICP-MS are covered in a reader-friendly format that a novice, who is carrying out elemental impurities testing in the pharmaceutical and nutraceutical communities, will find easy to understand.

The over-riding premise for biotechnology in this book is bringing novel products to market to substantially advance patient care and disease mitigation. Biotechnology, over its relatively brief existence of 40 years, has experienced a mercurial growth. The vast educational need for biotechnology information in this rapidly burgeoning field is a basic rationale here. However a more prominent underpinning is that, bringing biotech products to market for patient care involves success in the following four areas of engagement simultaneously - scientific advances for healthcare technologies, novel and varied products for untreated diseases, regulatory authorities, and biotech companies. Features Comprehensive coverage of biotechnology science topics used in development and manufacturing Addresses all the scientific technologies within biotechnology responsible for products on the market and the pipeline Presents business issues such as marketing and sales of the products, as well as companies engaged, and how biotech business has evolved

Provide readers and front line health care products manufacturers, R&D management and biotech laboratories all the information they need to know to develop a GMP oriented industry with trained and skilled personnel and manufacture products that meet GMP and regulatory requirements Covers basic quality concepts and the elements of vendor's assessment, qualification and approval required by the pharmaceutical educational institutions and professional certification bodies Provides stepwise guidance on how to evaluate, audit, qualify and approve an API and packaging material manufacturer and supplier to enhance the GMP within the industry Provides ready to use regulatory documentation, e.g. letter of commitment, Questionnaire, SOP etc. required for API and Packaging Materials contract Provided material can be easily tailored to incorporate changes to add in-house vendor's qualification requirements